At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
AP30663 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study of AP30663 Given Intravenously for Cardioversion in Patients With Atrial Fibrillation
In Brief
A Phase 2 clinical trial evaluating AP30663 and Placebo for Atrial Fibrillation. Completed, enrolled 66 participants across 15 sites in 2 countries.
Detailed Summary
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of one or more doses of AP30663 for cardioversion in adult participants with AF.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesDenmark, Hungary
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartSep 2019
First PostedOct 2020
Primary CompletionDec 2022
Study CompletionJan 2023
TodayJul 2026
First PostedOct 1, 2020
Enrollment StartSep 9, 2019
Primary CompletionDec 13, 2022
Study CompletionJan 23, 2023
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 5.8 years ago
Interventions
AP30663drug
Administer by intravenous infusion.
Placebodrug
Placebo matched to AP30663.